Regeneron a new Buy at UBS as Street undervalues Dupixent's future

UBS upgraded Regeneron Pharmaceuticals (REGN) to Buy, citing undervaluation and a strong pipeline of next-gen Dupixent candidates. The firm set a $978 price target, implying 30% upside from the recent close of $778.36. Regeneron's GF Value is $923.58, suggesting 15.7% undervaluation. The company's GF Score is 87/100, reflecting robust financial health and profitability. Insiders have sold $12.9M in shares over the past year, while institutional guru ownership remains high.

Regeneron Pharmaceuticals reported 84-week Phase III trial data for Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The trial showed Pasatru prevented new heterotopic ossification lesions and reduced flare-ups compared to placebo. Safety data remained consistent, with no deaths reported. Regulatory submissions are planned in several countries, including Japan.

Regeneron (REGN) reported 84-week data from the Phase 3 OPTIMA trial, showing Pasatru prevented new HO lesions in FOP patients. The trial met primary endpoints, with no new lesions from Week 56 to 84. Pasatru also reduced flare-ups and had a well-tolerated safety profile. REGN plans to start a Phase 3 study in children with FOP. REGN stock closed at $762.81, up 2.18%.

Regeneron Pharmaceuticals (Nasdaq: REGN) reported 84-week Phase III trial results for Pasatru (garetosmab-grts) in treating fibrodysplasia ossificans progressiva (FOP). The data showed sustained efficacy in stopping new bone growth and reducing flare-ups. REGN shares closed up 2.2% at $762.81 after the announcement. The findings were presented at the ASBMR Annual Meeting.

Regeneron announced 84-week results from its Phase 3 OPTIMA trial for Pasatru in adults with FOP, showing sustained efficacy in halting new bone growth and reducing flare-ups. The trial met its primary endpoint at 56 weeks and maintained results at 84 weeks. Pasatru was recently FDA-approved based on 56-week data. Regeneron plans to start a Phase 3 trial for adolescents and children with FOP later this year.

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.